<DOC>
	<DOCNO>NCT00322842</DOCNO>
	<brief_summary>This study evaluate safety plerixafor outcomes purely exploratory nature . One pre-specified outcome evaluate interval 10-11 hour dose plerixafor begin apheresis determine least 2-fold increase circulate CD34+ cell . Data protocol assist determination dose schedule future study .</brief_summary>
	<brief_title>Treatment With AMD3100 ( Plerixafor ) Non-Hodgkin 's Lymphoma Multiple Myeloma Patients</brief_title>
	<detailed_description>Participants non-Hodgkin 's lymphoma multiple myeloma undergone prior cyto-reductive chemotherapy autologously transplant treated combination plerixafor granulocyte colony-stimulating factor ( G-CSF ) mobilization regimen day prior apheresis . The change standard European care addition plerixafor G-CSF mobilize regimen . Participants undergo mobilization G-CSF ( 10 µg/kg day ) day prior apheresis receive plerixafor ( 240 µg/kg ) . Participants undergo apheresis 5 consecutive day order collect target number ( ≥ 5*10^6 ) CD34+ stem cells/kg . Participants transplant cell obtain G-CSF plerixafor mobilization regimen . The number CD34+ cell mobilize peripheral blood time plerixafor dose prior apheresis harvest apheresis product measure . The number apheresis session require obtain ≥ 5*10^6 CD34+ cells/kg also measure . Success transplantation ( ) evaluate time engraftment poly-morphonuclear leukocyte ( PMN ) platelet ( PLT ) . Participants follow durability transplant 12 month follow transplantation . This study previously post AnorMED , Inc . In November 2006 , AnorMED , Inc. acquire Genzyme Corporation . Genzyme Corporation sponsor trial .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>JM 3100</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Diagnosis nonHodgkin 's lymphoma ( NHL ) multiple myoloma ( MM ) eligible autologous transplantation No 3 prior regimen chemotherapy More 4 week since last cycle chemotherapy . Patient recover acute toxic effect prior chemotherapy . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 White blood cell ( WBC ) count &gt; 3.0*10^9/L Absolute polymorphonuclear cell ( PMN ) count &gt; 1.5*10^9/L Platelet ( PLT ) count &gt; 100*10^9/L Serum creatinine &lt; =2.2 mg/dL Serum glutamic oxaloacetic transaminase ( SGOT ) , serum glutamic pyruvic transaminase ( SGPT ) total bilirubin &lt; 2 x upper limit normal ( ULN ) Left ventricle ejection fraction &gt; 45 % normal echocardiogram multiplegated acquisition ( MUGA ) scan Negative human immunodeficiency virus ( HIV ) Women child bear potential agree use approve form contraception . Patients fail previous collection Brain metastasis carcinomatous meningitis History ventricular arrhythmia History paresthesias A comorbid condition , view investigator , render patient high risk treatment complication A residual acute medical condition result prior chemotherapy Acute infection Fever ( temp &gt; 38°C/100.4°F ) Patients whose actual body weight exceeds 150 % ideal body weight Patients previously receive experimental therapy within 4 week enrol study currently enrol another experimental study mobilization period Positive pregnancy test female patient Lactating female Patients childbearing potential unwilling implement adequate birth control . Patients deterioration clinical status laboratory parameter time enrolment transplant ( long meet entry criterion ) may remove study discretion treat physician , principal investigator , sponsor .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Non-Hodgkin 's lymphoma</keyword>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Stem cell mobilization</keyword>
</DOC>